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Modulation of Porcine Wound Repair with a
Transfected ErbB3 Gene and Relevant EGF-Like
Ligands
Martina I. Okwueze1, Nancy L. Cardwell1, Alonda C. Pollins1 and Lillian B. Nanney1,2
Our in vivo study used an ErbB3 receptor transfection strategy to determine if topical application of EGF-like
ligands would enhance repair. Partial-thickness porcine wounds transfected with adenoviral particles
containing an ErbB3 receptor gene or a vehicle b-galactosidase gene were introduced and wounds were
concomitantly supplied with a variety of EGF-like ligands – EGF, epiregulin (EPR), heparin binding EGF (HB-EGF),
and heregulin/neuregulin (HRG). Comparisons of cutaneous repair (resurfacing, dermal depth, proliferation,
macrophage infiltration, microvascular density, apoptosis) were assessed after a 5-day healing interval.
Differential effects were noted. In wounds transfected with additional ErbB3, either EPR or HB-EGF promoted
resurfacing greater than EGF, HRG, or controls. Dermal responses differed significantly after EPR or HB-EGF
treatments compared to EGF, HRG, ErbB3 only, or empty vehicle. Hallmarks of enhanced wound maturity were
noted in EPR- and HB-EGF-treated wounds transfected with ErbB3. Our data confirmed that an ErbB3-driven
pathway mediates a net positive influence in an in vivo model closely resembling human repair. The sensitivity
in this system was sufficient to reveal differential outcomes following stimulation with various EGF ligands. We
conclude that selective stimulation through an ErbB3-driven pathway shows promise as a therapeutic strategy to
hasten wound maturity.
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INTRODUCTION
The EGF family of growth factors and the ErbB1 receptor form
have long been implicated in migratory and proliferative
processes associated with malignant growth as well as the
benign transient growth patterns of cutaneous wound repair.
Highly similar ligands in this cytokine family include EGF
(Cohen and Elliot, 1963), epiregulin (EPR) (Toyoda et al.,
1995), heparin binding EGF (HB-EGF) (Higashiyama et al.,
1991), heregulin/neuregulin (HRG) (Burden and Yarden,
1997), amphiregulin (Shoyab et al., 1989), transforming
growth factor-a (Derynck et al., 1984), betacellulin (Shing
et al., 1993), and epigen (Strachan et al., 2001). Although
scientists were initially puzzled by the apparent biological
redundancy of highly similar ligands, cytokines within the
EGF family have now been grouped into subfamilies
based on subtle structural and functional similarities and
dissimilarities (Yarden and Sliwkowski, 2001; Draper et al.,
2003a, b). In vitro experiments with epithelial carcinoma
lines have increasingly provided evidence that differing
ligand/receptor affinities can trigger divergent downstream
signal transduction events (Graus-Porta et al., 1997; Wells,
1999; Olayioye et al., 2000; Draper et al., 2003a; Hynes and
Lane, 2005; Warren and Landgraf, 2006; Xue et al., 2006;
Yang et al., 2006). Although these pivotal distinctions are
under intense scrutiny in cancer biology, potential differential
effects have not been explored in the in vivo setting of wound
repair.
The existence of four unique transmembrane receptor
forms (ErbB1, ErbB2, ErbB3, and ErbB4) with the potential for
10 possible combinations of ErbB receptor dimers with
multiple ligands that can mediate ligand/receptor interaction
further compounds the potential diversity of responses that
can be evoked by differential binding, heterodimerization,
and downstream signaling (Wells, 1999; Motoyama et al.,
2002; Hynes and Lane, 2005; Lund et al., 2005). Simple in
vitro scratch assays have proven the existence of differential
signaling responses following wounding (Draper et al.,
2003a). However, the dynamic wound healing milieu within
an actual wound bed includes an interplay among sequential
inflammatory events and mediators, angiogenic forces,
matrix deposition, and remodeling, all of which are not
amenable to evaluation in the culture dish (Schaffer and
Nanney, 1996; Singer and Clark, 1999). Although in vitro
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approaches can document focal mechanisms, such studies
provide no assurance that a net biological impact will be
similarly observed in an in vivo system when various ligand
receptor combination are put to the test.
The present in vivo explorations are grounded in the
knowledge that endogenous levels of EGF and receptors
appear to be pivotal autocrine/paracrine/juxtacrine mole-
cules in many migratory and proliferative settings. Specifi-
cally, EGF and transforming growth factor-a have been
shown to promote re-epithelialization (Schultz et al., 1987;
Brown et al., 1989; Nanney, 1990; Andree et al., 1994). A
recent report indicated that EPR is more potent and effective
than either EGF or transforming growth factor-a in accelerat-
ing repair of murine excisional wounds (Draper et al.,
2003b). EPR was shown to increase mitogenesis through
the Ras/extracellular signal-regulated kinase mitogen-acti-
vated protein kinase signaling pathway (Draper et al., 2003a).
The HB-EGF ligand has likewise been implicated as another
important autocrine growth factor for human keratinocytes
(Piepkorn et al., 1998). Topical application of HB-EGF results
in autocrine and paracrine activity on the cellular level that
promotes wound healing (Nishi and Klagsbrun, 2004; Xu
et al., 2004; Shirakata et al., 2005). Not surprisingly another
ligand in the EGF family, HRG represents yet another potent
motility growth factor for normal and malignant keratinocytes
(Schelfhout et al., 2002; Yang et al., 2006). Interestingly, the
HRG family of ligands has a preferential affinity for the ErbB3
transmembrane receptor as opposed to the ErbB1 receptor
form. ErbB3 receptors differ from ErbB1 receptor forms in that
they lack tyrosine kinase activity within the cytoplasmic tail
(Fendly et al., 1994; Guy et al., 1994; Prigent and Gullick,
1994; Sliwkowski et al., 1994). This circumstance results in a
weak phosphorylation capability and differing outcome
possibilities in signal transduction pathways. Owing to this
kinase deficiency, ErbB3 receptor must pair with ErbB1,
ErbB2, or ErbB4 receptor forms to create heterodimers
capable of activating downstream signaling (Kraus et al.,
1993). Although lacking in ligand binding abilities, the ErbB2
receptor form has functioned most effectively as a preferred
dimer forming partner (Olayioye et al., 2000; Rubin and
Yarden, 2001). When it forms heterodimers with ErbB3, the
resulting combination exhibits an increased binding affinity.
In fact, this heterodimer combination evokes extremely
potent signaling that is often associated with undesirable
neoplastic growth and poorer prognosis for breast cancer
victims (Waterman et al., 1999; Xue et al., 2006). Even
though the bulk of these findings with EGF-like ligands and
their ErbB receptor forms are emerging from cancer biology,
molecules within this pathway are likely contributors to
transient signaling occurring within the complexities of the
wound healing environment.
The purpose of this study was to determine the biological
effect when additional ErbB3 receptors were introduced into
the wound healing environment. This study was also
designed to assess whether topical application of various
EGF-like ligands had the potential to enhance repair in a
synergistic but differential manner. A partial-thickness por-
cine excisional model was specifically selected. Porcine skin
exhibits a host of similarities to human skin making it one of
the models of choice for development of cutaneous pre-
clinical strategies (Roesel and Nanney, 1995; Bennett et al.,
2001; Wang et al., 2001). Previous studies have established
that pharmacologic levels of the EGF ligand delivered in
either a conventional topical formation or with a gene
transfection strategy can successfully accelerate resurfacing
in this biological model (Nanney, 1990; Andree et al., 1994).
Furthermore, a boosting of ErbB1 gene expression has a
proven capacity to hasten repair, thereby suggesting that
inadequate receptor numbers may be a rate-limiting factor
during healing (Nanney et al., 2000). In this study, a wide
variety of wound healing parameters (re-epithelialization,
dermal depth, proliferation, macrophage infiltration, capil-
lary density, apoptosis) were assessed following a transient
transfection strategy for introduction of ErbB3 receptors in
concert with enhanced pharmacologic delivery of EGF-like
ligands.
RESULTS
In vitro studies have clearly indicated that the ErbB signaling
cascade is known to exert influence on a multitude of cellular
processes (Graus-Porta et al., 1997). For this reason, our in
vivo study was designed to detect possible biological
outcomes on diverse aspects of cutaneous repair. Partial-
thickness excisional wound beds were transiently transfected
with ErbB3 to shift the in vivo system in favor of forming
either ErbB3 homodimer or ErbB3 heterodimer receptor
combinations. Wounds were then supplemented with a
range of EGF-like ligands. The goal was to determine if the
porcine model provided sufficient sensitivity to detect
differential effects to combinatorial possibilities within the
ligand/ErbB3 receptor pathway.
Assessment of re-epithelialization
As this family of receptors and their highly similar ligands are
predominantly known for their effects on epithelial cells, we
hypothesized that prime effects would be observed through
assessment of keratinocyte populations participating in
epidermal resurfacing. Wounds receiving ErbB3 gene trans-
fection followed by additional treatments with exogenous
cytokines in the EGF ligand family exhibited accelerated
resurfacing when compared to either control wounds
transfected with ErbB3 in the absence of exogenous EGF-
like ligands or wounds transfected with the empty vector and
not given the benefit of topical cytokines. Specifically, topical
delivery of either the EPR or HB-EGF ligand to wounds
simultaneously transfected with ErbB3 receptor gene showed
statistically significant improvements in resurfacing rates of
7576% (Po0.0001) and 7075% (Po0.002) when com-
pared to LacZ control wounds (transfected with empty vector)
where endogenous levels of ErbB3 receptors prevailed and a
modest resurfacing rate of 3177% was noted after 5 days of
healing (Figure 1a). The degree of resurfacing in wounds
enhanced with ErbB3 but supplied instead with exogenous
EGF or HRG ligand was less dramatic at 5776 or 5177%,
respectively (P40.05). Wounds enhanced only by transfec-
tion with ErbB3 receptor but not given the benefit of topical
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treatment with exogenous ligand exhibited limited resurfa-
cing (4278%) and were significantly slower in resurfacing
than wounds receiving the topical boosting with either EPR
(Po0.011) or HB-EGF (Po0.019). Wounds were evaluated to
see whether ligand or ligandþ ErbB3 was most beneficial on
the extent of epidermal resurfacing. Only the ErbB3þHB-
EGF combination proved significantly more resurface than
ligand-only treatment (Po0.01). Taken together, these data
suggest that wounds that were shifted to favor ErbB3
homodimer and heterodimer combinations along with the
abundant availability of certain exogenous EGF ligands have
the potential to resurface more rapidly. Not surprisingly, the
degree of epidermal resurfacing was dependent on the
particular EGF-like ligand that was delivered at a pharmaco-
logic level. The ErbB3þHB-EGF combination treatment was
the clear winner in influencing the extent of epidermal
regrowth in the in vivo wound environment.
Visible morphological differences in the character of
healing epidermis were also observed among the treatment
categories (Figure 2). A four-tiered, semiquantitative grading
system based on epithelial presence, degree of stratification,
degree of differentiation as well as maturational features of
the granulation tissue was devised to capture and report these
differences among the treatment groups (Table 1). Control
wounds (those receiving the empty vector instead of the
receptor construct) exhibited an immature healing response
characterized by a loose granulation tissue formation with no
epithelial coverage (Figure 2a). This set of immature features
was arbitrarily assigned and rated as a Class I response





















































































Figure 1. Quantitative morphometric analysis of resurfacing, neodermal thickness, and granulation tissue thickness in wounds transfected with adenovirally
delivered ErbB3. Porcine wounds were studied at 5 days after injury and were divided into 10 different treatment groups: Ad:LacZþKY (control),
ErbB3þ individual ligands, LacZ vectorþ individual ligands, and ErbB3 without ligand. (a) Re-epithelialization is expressed as a percentage of wound
resurfacing. Wounds treated with ErbB3þ EPR or ErbB3þHB-EGF were significantly more resurfaced compared to LacZ control (*Po0.0001 or **Po0.002).
Treatment with ErbB3þ EPR or ErbB3þHB-EGF also showed significant resurfacing compared to wounds treated with ErbB3 only (#Po0.01). Resurfacing of the
ErbB3þHB-EGF group was significantly more resurfaced compared to the LacZþHB-EGF wounds (Po0.01). (b) Granulation tissue thickness at 5 days after
injury. Wounds treated with ErbB3þ EGF (*Po0.01), ErbB3þ EPR (**Po0.001), ErbB3þHB-EGF (***Po0.0001), and ErbB3þHRG (***Po0.0001) were
significantly increased from the LacZ control. Treatment with ErbB3þHB-EGF showed enhanced levels of granulation tissue when compared against ErbB3
alone (#Po0.033). In comparing LacZþ individual ligand against ErbB3þ individual ligand, the combination of receptorþ ligand produced significantly higher
levels of granulation tissue for EPR (þPo0.007), HB-EGF (þþPo0.001), HRG (þþþPo0.03). ErbB3 alone showed significantly more granulation tissue
compared to the empty LacZ treatment (þþþþPo0.019). (c) Neodermal maturation as evidenced by compacted dermal thickness at 5 days after treatment.
Significant compaction of the neodermis was noted in the ErbB3þ EPR (*Po0.009) or ErbB3þHB-EGF (**Po0.0001) treatments as compared to LacZ control.
The ErbB3þHB-EGF neodermis was significantly thinner than the ErbB3 alone (#Po0.001).
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response (Figure 2g) The ErbB3þ EGF group of wounds
showed the presence of a basal layer of epithelium with no
stratification covering a slightly higher density of dermal cells
interspersed between a scant accumulation of extracellular
matrix (Class II) (Figure 2b). The ErbB3þ EPR wound set
displayed epidermal stratification and neodermal cellular
influx (Class III) (Figure 2c), whereas the ErbB3þHB-EGF
group of wounds showed robust epidermal coverage with an
increased degree of stratification (Figure 2d). This hyper-
trophic epidermis overlying a neodermis containing fewer
cells dispersed between an ever increasing extracellular
matrix (Class IV). The ErbB3þHRG group of wounds were
placed into the Class II category, as after 5 days of healing,
they exhibited minimal reconstitution of the basal layer of
epithelium with no stratification similar to the wounds treated
with EGF (Figure 2e). Finally, the group of wounds receiving
ErbB3 receptor overexpression without the benefit of topical
ligands were mixed in their morphological appearance and
were classified as having a combination of Class II and III
responses (Figure 2f). Such wounds with only ErbB3
enhancement showed evidence of modest resurfacing with
early stratification of the epidermis and a granulation tissue
that was still highly cellular and loosely organized.
Assessment of granulation tissue and neodermis
Although EGF-like ligands have been primarily noted for their
impact on epithelial structures, the impact of the various
ligand treatments on the connective tissues within the wound
bed was qualitatively unique as discerned from Figure 2.
These differences were also quantitatively evaluated and
displayed in Figure 1b and c.
Granulation tissue thickness was the assessment tool of
choice for those treatment groups that were either barely
resurfaced or not resurfaced at all (highly immature) (Figure
2a and g). Collection of measurements was restricted to the
central areas within the wound bed. Depth measurements of
the loosely arranged granulation tissue were taken from the
still exposed surface of the wound bed (regions not yet re-
epithelialized between the epithelial islands) down to the
underlying non-wounded dermis in these partial-thickness
wounds. Granulation tissue depths were significantly higher
in ErbB3-transfected wounds topically treated with each
of the ligands: EGF (Po0.012), EPR (Po0.01), HB-EGF
(Po0.0001), and HRG (Po0.0001) as compared to LacZþ
KY-treated control wounds (Figure 1b). In comparing these,
same ErbB3þ ligand wounds against the ErbB3 (receptor
only) control wounds, only the ErbB3þHB-EGF treatment
group proved statistically stimulated (Po0.033). In all
but the EGF treatment, the addition of ErbB3þ ligand proved
statistically superior to ligand alone treatment (EPR:
Po0.007; HB-EGF: Po0.001; HRG: Po0.03, respectively).





LacZ + KY ErbB3 + EGF
ErbB3 + HBEGF
ErbB3 + KYErbB3 + HRG
ErbB3 + EPR
NormalLacZ + EGF
Figure 2. Morphologic changes after growth factor treatments using a
four-class system based on epithelial migration and stratification. Maturity
and the extent of epithelial healing varied considerably between treatment
groups. (a) LacZþKY (control): Class I, poor healing overall, no epithelial
coverage, abundant fibrin, and poorly organized granulation tissue.
(b) ErbB3þ EGF: Class II, evidence of epithelial coverage with no stratification,
nascent neodermis. (c) ErbB3þ EPR: Class IV, presence of a stratified and
differentiated epidermis with highly mature neodermis. (d) ErbB3þHB-EGF:
Class III, matured epithelial coverage with decreased cellularity in the
neodermis due to maturation. (e) ErbB3þHRG: Class II, some resurfacing
with basal layer of epithelium over an immature granulation tissue.
(f) ErbB3þKY: Class II and III, some epithelial islands at the surface and a
robust granulation tissue. (g) LacZþ EGF: Class I, a fibrin covering, no
epidermis, and immature granulation tissue. (h) Normal pig skin with a
stratified keratinized epidermis and dense irregular connective tissue
in the dermis Trichrome staining (GT, granulation tissue; Epi, epidermis;
ND, neodermis; D, dermis) (bar¼100 mm; original magnification  10).
Table 1. The epidermal resurfacing measurements





Class I Little or no epithelial layer
Class II 1–3 cell layer deep coverage with little or no
stratification
Class III Epidermal coverage with stratification of 3–7 cell layers
Class IV Epidermal coverage with hyperproliferative epidermis
and downward projections of rete ridges into neodermis
For visual evaluation of epithelial maturity, a four-class system based on
epithelial migration and stratification was performed and described
below.
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LacZ control indicating that pharmacologic dosages of ligand
alone are ineffectual in the absence of receptor enhance-
ment. The thickness of the granulation tissue is a crude
assessment tool that represents the composite of new blood
vessels, fibroblasts, macrophages, and extracellular matrix;
nevertheless, these data suggest that the combined therapy
of enhancement with ErbB3 receptor supplemented with
specific EGF-like ligands can effectively modulate the
thickness of this connective tissue. These data also indicate
that the triggering of an ErbB3 predominant signaling
pathway has a wide-reaching biological impact on both the
epidermal and connective tissue components of the wound
healing response.
Several of the treatment groups showed remarkable
maturity at 5 days after wounding (Figure 2c and d). To
quantify these data with accuracy, we also assessed the depth
of the neodermis. Measurements of neodermal depth were
collected in a differing manner from granulation tissue depth
(Nanney, 1990; Roesel and Nanney, 1995; Nanney et al.,
2000). Neodermal depth measurements were selectively
taken only beneath those focal areas that were resurfaced
with an epidermis. These neodermal measurements also
captured selective differences between the EGF ligand
treatments, as did the granulation tissue measurements.
The ErbB3-transfected wounds supplemented with either
the EPR (Po0.009) or HB-EGF ligand (Po0.0001) showed
dramatic reductions in thickness within the maturing
neodermis when compared to the LacZ control wounds
(Figure 1c). Only the ErbB3þHB-EGF treatment proved to
enhance the maturation of the dermis in a significant manner
as compared against boosting only the ErbB3 receptor
(Po0.001). Treatment of wounds with ligand alone did not
result in a significant impact on the depth of the neodermis
(Figure 1c). The ErbB3þ EPR and ErbB3þHB-EGF wounds
were morphologically mature and extensively resurfaced at 5
days after injury (Figure 2c and d). With both treatments,
the appearance of the wound bed had progressed beyond
an immature, loose connective tissue and was instead
characterized as a more compressed and denser type of
connective tissue. Stated differently, measurements of neo-
dermal depth (assessed as the distance from the dermal–epi-
dermal junction to the interface of the underlying non-
wounded dermis) were significantly diminished (compressed
and consolidated) as compared to all other treatment groups.
Thus, decreased thickness equates with maturity and does not
represent inhibitory influences to the wound healing process.
Assessment of microvascular density
The density of the capillary network within the neodermis or
granulation tissue was qualitatively and quantitatively
assessed for each treatment group (Figures 3 and 4). All
groups transfected with ErbB3 receptor and additionally
treated with any of the topical EGF-like ligands used in this
study displayed statistically significant decreases in the
percentage of wound area occupied by capillary networks
compared to control wounds that received no transfection
with ErbB3 (Po0.0001, Figures 3 and 4b–e). It has long been
known that the neovascularity that characterizes immature
granulation tissue gradually diminishes as wounds mature
(Roesel and Nanney, 1995; Schaffer and Nanney, 1996).
Thus, it was not unexpected that the density of the
microvasculature was reduced by 3- to 4-fold in all treatment
groups compared to the immature appearing control wounds
that received only empty vector (Figures 3 and 4a).
Surprisingly, wounds boosted with ErbB3 without the benefit
of exogenously applied ligands showed the identical dimin-
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Figure 3. Quantitative morphometric analysis of neovascular responses to
ErbB3 transfection and subsequent treatment with ligands. Compared to
control wounds, all treatment groups showed significant reductions in the





Figure 4. Capillary endothelia and density identified in the maturing
neodermis after 5 days of healing using antisera for Von Willebrand.
(a) Ad:LacZ (control) wound shows extensive capillary networks in the
immature granulation tissue. (b) ErbB3þ EGF treatment shows a modest
number of capillaries. (c) ErbB3þ EPR treatment and (d) ErbB3þHB-EGF
treatment show relatively fewer capillaries than controls. (e) ErbB3þHRG
treatment and (f) ErbB3-only treatment show staining for few capillaries
(bar¼ 50 mm; original magnification  20).
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supplemented with EGF-like ligands (Figures 3 and 4f). These
data suggest that the extent of capillary density in the wound
bed is primarily influenced by ErbB3 and is apparently not
dependent on EGF-like ligands.
Figure 4 depicts representative photomicrographs high-
lighting immunopositive endothelial cells highlighting the
capillary networks. The control wounds (not having the
benefit of additional transfection with ErbB3 (Figure 4a))
show extensive capillary density, a circumstance that is
consistent with their immaturity within the wound bed as
compared to the most mature (accelerated) treatment groups
depicted in either ErbB3þ EPR or ErbB3þHB-EGF wounds
(Figure 4c and d).
Assessment of cell proliferation
Immunostaining with the Ki67 antigen was used to determine
actively proliferating cells (predominantly fibroblasts) within
the granulation tissue/neodermal regions of the healing
wounds. All treatment groups demonstrated statistically
significant decreases in proliferating cells at 5 days after
wounding compared to the control sets of wounds
(Po0.001). When numbers of proliferative cell within the
dermal region were correlated with features of wound
maturity (Figure 2), it was apparent that higher numbers of
proliferating cells (presumably fibroblasts) were characteristic
features of immature wounds; that is, those in the LacZ,
ErbB3þHRG, and ErbB3þKY groups (Figure 5). This was a
confirmatory finding as wounds that have reached the
remodeling phase are characterized by extensive production
of extracellular matrix proteins (Singer and Clark, 1999).
The level of proliferating dermal cells was simultaneously
compared among transfected ErbB3 wounds receiving addi-
tional exogenous treatments with the various ligands. ErbB3-
transfected wounds supplied with either the EPR or HB-EGF
exogenous ligand exhibited statistically fewer proliferating
cells than the HRG-treated group (Po0.005). This suggests
that all EGF-like ligands evoke differential responses in this
parameter of dermal assessment. The fact that ErbB3þHB-
EGF wounds showed significantly lower numbers of prolif-
erating dermal cells than the ErbB3-only wounds suggests a
synergistic impact produced by this ErbB3 receptors and this
particular ligand (P¼ 0.03).
Assessment of macrophage influx
To gauge the extent of the inflammatory process, the numbers
of infiltrating macrophages were assessed after 5 days of
healing. The control set of wounds (LacZþ empty gel
treatment) showed the greatest number of macrophages still
persisting within the wound beds (Figure 6). By contrast,
wounds treated with either ErbB3þ EPR or ErbB3þHB-EGF
exhibited the fewest infiltrating macrophages as compared to
control group receiving the empty vector devoid of ErbB3
(Po0.002). Wounds treated with ErbB3 only showed an
intermediate reduction in macrophages as compared to the
LacZ alone or the ErbB3þ EPR or ErbB3þHBEGF. Long-
established reports suggest that macrophage influx begins to
decline as wounds mature (Singer and Clark, 1999). The
present qualitative and quantitative data suggest that by the
time of tissue harvesting at day 5 after wounding, the
inflammatory phase had long since peaked in those wounds
with accelerated healing characteristics – the ErbB3þ EPR or
ErbB3þHB-EGF wounds (Po0.02, Figure 6).
Assessment of apoptosis
Apoptotic cells become increasingly more prevalent as
wounds mature (Danielsen and Maihle, 2002). To confirm
the differential status in wound maturity among the various
treatment groups, apoptotic cells were visualized using a
TUNEL assay followed by quantitative morphometric ana-
lysis. A significant 3-fold difference was noted in the
comparison between LacZ transfection and ErbB3 transfec-
tion in the absence of exogenous ligand treatment Po0.04
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Figure 5. Quantitative morphometric analysis of proliferative cells within
the dermis/granulation tissue at 5 days post-wounding. All ligand-treated
groups showed significant reductions in cell proliferation compared to control
(*Po0.0001). ErbB3þ EPR and ErbB3þHB-EGF treatments were also
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Figure 6. Macrophage density evaluating inflammatory influx at 5 days after
injury when treated topically with EGF-like ligands. Wounds treated with
ErbB3þ EPR or ErbB3þHB-EGF showed significant reduction in macrophage
counts compared to control (*Po0.002). ErbB3 without ligand stimulation
also had a significant reduction in the inflammatory process compared to the
empty vector control (**Po0.01).
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the process of apoptosis. The ErbB3þ EPR and ErbB3þHB-
EGF treatment groups revealed an 8-fold higher number of
apoptotic cells compared to the LacZ-transfected control
wounds (Po0.001). This indicates a synergistic affect by
these EGF-like ligands on apoptosis in the presence of
boosted ErbB3 receptor levels.
Global assessment of excessive ErbB3 receptor alone versus
excessive ErbB3þ ligands
As numerous combinatorial conditions were investigated in
our study alongside a host of wound healing parameters,
these data were assembled in tabular format to provide an
overall summation of the multitude of biological outcomes
(Table 2). This preliminary in vivo study was designed to
answer (a) whether or not transient transfection of ErbB3
receptor alone in a complex biological system could produce
a measurable impact on wound healing activities, (b) whether
or not exogenous ligands in the presence of transfected ErbB3
could produce an additive or synergistic impact, (c) whether
or not there was sufficient sensitivity in a biological model to
detect a differential influence among highly similar ligands.
As summarized in Table 2, the gene transfection of ErbB3
receptors in the absence of any other supplementation
resulted in a moderate biological impact on the parameters
of resurfacing, cell proliferation in the dermis, the number of
macrophages in the wound bed, and apoptosis. Presumably
these outcomes are mediated through binding of the
available pool of endogenous ligands within the wound
bed. Addition of pharmacological levels of EGF-like ligands
produced noticeable global effects that in several cases were
additive. Differential responses were noted in the degree of
response to certain ligands and in the various parameters that
were affected. For example, EGF treatments or HRG
treatments produced a moderate impact in comparison to
EPR and HB-EGF on the parameter of resurfacing, and
macrophage density. Conversely, when the parameter of
apoptosis was evaluated, the HRG response was modest in
comparison to EGF, EPR, and HB-EGF.
DISCUSSION
A transient transfection strategy was employed to shift
endogenous receptor patterns to favor of ErbB3 homodimer
or heterodimer combinations. Specifically, our in vivo data
provide evidence that the ErbB3 receptor functions to
accelerate wound repair and shift reparative events toward
maturation following the exogenous application of either the
EPR or HB-EGF ligands. For years, it has been known that
each ErbB receptor displays a unique pattern of phosphoryla-
tion sites that recruit various secondary signaling proteins
upon ligand binding (Wells, 1999). Although the combina-
tion of multiple EGF-like ligands and 10 possible receptor
dimers of the ErbB system have been well documented
in vitro, and are under intense scrutiny in the field of cancer
biology, and have become the basis for targeted inhibitors for
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Figure 7. Wound maturation evaluated by the numbers of apoptotic cells
within the dermis following treatment. Treatments with ErbB3þ EGF,
ErbB3þ EPR, and ErbB3þHB-EGF produced significant increases in
apoptosis when compared to control (*Po0.001). ErbB3þ EGF, ErbB3þ EPR,
and ErbB3þHB-EGF treatments showed significantly more apoptotic cells
compared to the ErbB3 without ligand (#Po0.001) treatment group. And
ErbB3þ EPR and ErbB3þHB-EGF treatments showed significantly greater
levels of apoptosis than the ErbB3þHRG treatment (þPo0.01).
Table 2. Summary of biological impact of ErbB3 receptor and ligands on various wound healing parameters
Treatment
Parameter Only ErbB3 ErbB3+EPR ErbB3+HB-EGF ErbB3+EGF ErbB3+HRG
Epidermal resurfacing M1 H H M M
Granulation tissue depth H H H M/L H
Neodermal depth L H H L L
Neovascularization H1 H H H H
Dermal cell proliferation M1 H H M/H M
Macrophage density M1 H H M M
Apoptosis M1 H H H M
Key: H, high or substantial biological impact; M, moderate or intermediate biological impact; L, low or little biological impact.
1Biological impact that did not require pharmacologic levels of exogenous EGF-like ligand.
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2002; Hynes and Lane, 2005), this ligand/receptor explora-
tion has not extended into the study of wound repair.
Previous reports have documented a positive role for the EGF
ligands and ErbB1 signaling pathway in acceleration of
wound repair (Brown et al., 1989; Nanney, 1990; Wenczak
et al., 1992; Andree et al., 1994; Nanney et al., 2000; Draper
et al., 2003b). The current report provides proof-of-principle
within a highly relevant porcine model that manipulation of
the wound environment in favor of ErbB3 receptor combina-
tions can evoke net positive consequences within the in vivo
complexities of the wound milieu. This evidence suggests
that ErbB3 and relevant ligands could be harnessed for
a therapeutic advantage for cutaneous wound repair in
humans.
To our knowledge, this is the first attempt to examine the
sensitivity of combinatorial ligands with another ErbB
receptor form within an in vivo model of repair. Localization
of the ErbB3 receptor form to the upper strata of epidermis in
normal skin and healing skin as opposed to ErbB1 in the
proliferating compartment suggested its prime function in
epidermal differentiation and maturation (Nanney et al.,
1984; Wenczak et al., 1992; De Potter et al., 2001; Piepkorn
et al., 2003). The in vivo gene transfection treating
circumstances with ErbB3 favored a superior impact on
healing following the exogenous application of pharmaco-
logic levels of either EPR or HB-EGF. By contrast, the modest
healing outcomes that were observed following either EGF or
HRG treatments suggest that although EGF ligands have a
high degree of similarity, each specific ligand evokes
downstream responses that differentially affect the healing
process.
A variety of EGF-like ligands were selected for our
comparisons because each has selective binding affinities
for homodimer and heterodimer forms in the ErbB receptor
family. EGF was chosen as previous work has already proven
its capability to accelerate epithelialization by 20% (Nanney,
1990; Andree et al., 1994; Nanney et al., 2000). In vitro
studies have shown that an EGF-dependent pathway through
ErbB3 is linked to phosphatidylinositol 3-kinase downstream
signaling (Kim et al., 1994). Epiregulin was selected as a
result of previous reports that have documented enhanced
wound maturity when either wounded keratinocytes or in
vivo wounds are supplied with EPR (Draper et al., 2003a, b).
Whereas this study specifically evaluated healing in the
context of ErbB3 dominance, the differential findings for EGF
and EPR were in concordance with our earlier findings in the
full-thickness murine excisional wound model that showed a
10-fold lower dose of topical EPR promoted greater
epidermal proliferation and thickening than EGF (Draper
et al., 2003b).
The HB-EGF ligand was included in this study for multiple
reasons. This EGF-like peptide is representative of an EGF-
like molecule exhibiting a special affinity for heparin.
Secondarily, it has a high binding affinity for ErbB3 receptor
forms, is normally secreted by macrophages in the wound
bed, and can downregulate adhesion molecules and decrease
inflammatory infiltrates (Higashiyama et al., 1991; Xia et al.,
2003). Multiple lines of evidence have documented its
presence in normal skin, its endogenous production in burn
wounds, and positive in vivo reparative outcomes following
topical application (McCarthy et al., 1996; Downing et al.,
1997; Cribbs et al., 1998, 2002; Varani et al., 2001). Further
evidence of its essential role during wound repair has been
demonstrated by blockade of endogenously produced HB-
EGF ligand with a highly specific antagonist resulting in
diminished wound closure in epithelial wound healing (Xu
et al., 2004). The results of our study confirm that the strategy
of supplying exogenous HB-EGF in concert with a back-
ground tipped in favor of ErbB3 receptors has an additive
effect on wound healing that exceeds that of EGF or control
groups. This treatment was clearly the most effective in terms
of accelerating the aspects associated with epidermal
resurfacing and the generation of a maturation of the dermal
region.
Finally, HRG was included as the ErbB3 receptor is
regarded as the preferred receptor for this EGF-like
ligand (Riese et al., 1995). Earlier studies with HRG
identified this ligand as a motility factor for keratinocytes
(Danilenko et al., 1995a, b; Schelfhout et al., 2002; Zhang
and Segall, 2006). Breast cancer studies indicate rac
signaling that is evoked downstream of HRG binding to
ErbB3 (Yang et al., 2006). The extracellular domains of
the ErbB3 receptor are particularly prone to ligand-
independent oligomerization of multiple receptor molecules
at the plasma membrane (Landgraf and Eisenberg, 2000).
In the in vitro setting, such clusters of oligomers are
destabilized by the binding of HRG; thus, this ligand
preferentially facilitates the heterodimerization of ErbB3
with ErbB2, which consequently results in a strong propensity
to stimulate cell proliferation (Rubin and Yarden, 2001;
Kani et al., 2005; Yang et al., 2006). In the current in vivo
study, topical application of HRG in concert with transfected
ErbB3 receptor was not significantly different from the
wound response with transfected ErbB3 in the absence of
any exogenous ligand; however, compared to control
wounds receiving empty vector (no boosting of receptor),
the wound repair was nevertheless accelerated. As in vitro
evidence suggests that HRG treatment activates ErbB2/ErbB3
heterodimers, we suspect that similar mechanisms were
responsible for our observations within the porcine wound
healing model (Jackson et al., 2004; Lund et al., 2005; Xue
et al., 2006).
To gauge the impact of this ligand/ErbB3 receptor
signaling system on dermal events, dual assessment techni-
ques became necessary because the maturity of the wound
bed varied greatly among the treatment groups. It was
impossible to find the single most accurate assessment tool
that accurately portrayed both immature and highly mature
wounds. Wounds that were highly immature at 5 days after
injury were largely unresurfaced meaning that we could
easily collect a sufficient number of data points for an
accurate and true portrait of granulation tissue depth. By
contrast, wounds that were largely resurfaced (more mature)
were more accurately portrayed by collecting neodermal
depth measurements (thickness) beneath the epidermal sur-
face. In the mature wounds, there were only a few focal areas
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within the wound where a granulation tissue depth could be
made. To avoid skewing the data, we depicted both
granulation tissue depth and neodermal depth to maintain
consistency. Nonetheless, by either strategy, we noted that
two of our receptor/ligand combinations (ErbB3þHB-EGF or
ErbB3þ EPR) exhibited the greatest impact on events within
the dermal region. Whether these were direct effects
mediated through ligand/receptor activation or were indir-
ectly influenced by the maturity of the extent of resurfacing
remain open questions.
Our previous porcine studies have shown that it is an
excellent model to detect quantitative changes in capillary
density after treatment with a variety of anti- or pro-angiogenic
compounds (Roesel and Nanney, 1995; Nanney et al., 2001).
These studies and current dogma also documented that wound
maturity is characterized by a diminution in the capillary
density (Singer and Clark, 1999). The significant maturation
seen in the majority of the ErbB3-transfected wounds following
many of the ligand treatments indicated that after 5 days, most
treatment groups were well past the peak period of granulation
tissue production that is characterized by a plethora of new
capillaries. Not surprisingly, both qualitative and quantitative
assessments showed that microvascular density had dimin-
ished to minimal levels compared to controls. Another
indicator of wound maturity is the influx of macrophages into
the wound bed. In the absence of infection, macrophage
numbers typically peak between 3 and 5 days and then
decline. This pattern was evident when macrophage numbers
were quantified. Thus, declining capillary densities as well-
diminished residual macrophage numbers provided supporting
evidence of a generalized accelerated maturation response in
the majority of the treatment groups.
ErbB receptor involvement in apoptotic signaling is not a
novel finding. ErbB receptors have been shown to play an
important role in apoptosis during embryonic tissue devel-
opment, in normal adult tissue maintenance such as wound
healing, and under the more negative circumstances of tumor
development and progression (Adamson and Wiley, 1997;
Gresik et al., 1998; Olayioye et al., 2000). Our data suggest
that the ErbB3 receptor alone has no significant effect on
apoptosis; however, topical application of EGF, EPR, and HB-
EGF onto the background of ErbB3 overexpression resulted
in a significantly greater apoptotic response. The net effect
after treatment with ErbB3þ ligand (HB-EGF or EPR) is a
significant reduction in inflammation, angiogenesis, cell
proliferation, and an increased apoptotic rate as compared
to all other treatments or controls. Stated differently, the
combination of a ligandþ transient receptor transfection
strategy resulted in accelerating the repair of porcine
partial-thickness wounds as compared to control, suggesting
an additive response of both the receptor and topical
application of the EGF-like ligands. Our study was designed
to detect the gross biological net effect. Whether the apoptotic
rate was directly manipulated from endogenous levels of
ligands in the wound bed or whether the increase in apoptotic
cells was an indirect product remains an open question.
In conclusion, quantitative measurements collected from
the in vivo porcine model provide a positive indicator that
topical cytokine treatments of wounds transiently supplied
with ErbB3 receptors can generate an additive biological
outcome that appears favorable. None of the ligands alone
were able to significantly enhance epithelialization or dermal
development in the absence of boosting of the ErbB3 receptor
form. These findings support the theory that past studies with
EGF-like cytokines have shown disappointing results as ErbB
receptors have been a rate-limiting factor. Additionally,
morphological factors such as the degree of epidermal
stratification and differentiation give further credence to the
notion that the choice of ligand (HB-EGF in the present
report) could have a defining impact on the quality of the
reparative process. Considered in the context of previous
ErbB1 studies, this study indicates that the signaling pathways
based on either ErbB1 and/or the ErbB3 receptor forms can
serve to accelerate multi-factorial aspects of cutaneous




Nine adolescent Yorkshire pigs weighing approximately 50–60 lbs
were housed, fed, and treated in accordance with protocols
approved by the IACUC at Vanderbilt University Medical Center.
The porcine excisional wound model utilized in these studies was
identical to our previously described procedures (Nanney, 1990;
Roesel and Nanney, 1995; Nanney et al., 2000, 2001). Animals
were anesthetized with an intramuscular injection of Ketamine
(2.2 mg/kg), Telazol (4.4 mg/kg), and Xylazine (2.2 mg/kg). The
dorsal surface of the pig was clipped, shaved from shoulder to
flank, and disinfected with Betadine soap. In a sterile manner, four
longitudinal partial-thickness wounds were created to a depth of
1,560mm with a Zimmer dermatome. A series of individual
1.5 1.5 inch excisional wounds were created by placement of
multiple bridges consisting of skin grafts. Following hemostasis,
wounds were transfected with recombinant adenoviral particles
containing ErbB3 receptor gene or a vehicle b-galactosidase gene
(LacZ). After topical gel formulations containing EGF-like ligands
were applied, wounds were covered with Op-Site semiocclusive
dressings. Dressings were removed daily. Wounds were gently
cleansed with saline and then each wound received a fresh dosing
with EGF ligands. Occlusive bandages were reapplied to keep the
gel formulations in position and to keep the wounds hydrated. For
pain control, animals received 25 mg/hour Duragesic patches for
3 days (Fentanyl transdermal system). Pigs were killed at 5 days after
wounding. Random slices were removed from each wound, fixed in
10% neutral buffered formalin, and embedded in paraffin.
Adenovirus transfection and treatment groups
Adenovirus particles were modified through homologous recombi-
nation techniques to contain the receptor sequences for ErbB3
(Ad-Easy Vector System, Qbiogene, Carlsbad, CA). After confirmation
through Western analysis of production of functional proteins the
adenovirus particles (108 p.f.u.) were deposited in the wound bed as
we have previously reported (Nanney et al., 2000). The various EGF-
like ligands (1.0 mg/ml) were delivered in a gel matrix of 0.5 ml KY
lubricating gel (Johnson & Johnson, New Brunswick, NJ) and placed
on the wound bed. We have previously reported the biological
1038 Journal of Investigative Dermatology (2007), Volume 127
MI Okwueze et al.
ErbB3 and Porcine Wound Repair
activity of these EGF ligands delivered in simple gel formulations at
the 1 mg/ml concentration (Nanney et al., 2000). The following EGF-
like ligands and concentrations were used: EGF (166.7 nM; Upstate
CSS, Lake Placid, NY), EPR (200 nM; a kind gift from the Taisho
Pharmaceutical Co., Saitama, Japan), HB-EGF (105 nM; R&D Systems
Inc., Minneapolis, MN), and HRG-a (143 nM; R&D Systems Inc.,
Minneapolis, MN). These cytokines were topically applied in the KY
formulation at a standardized 1mg/ml dose on a daily basis. Ten
different wound treatments groups were evaluated. Wounds were
transfected with ErbB3 receptorsþ individual ligands, or were
transfected with the empty Ad:LacZ vectorþ individual ligands.
Control wounds were transfected with the adenovirus containing
LacZ gene and treated topically with the gel formulation (containing
no ligand) to maintain identical moisture conditions or transfected
with ErbB3þKY (no ligand). To confirm the success of our
transfection technique, quantitative reverse transcriptase-PCR was
performed on 48 hours wound samples and showed a 9-fold increase
in ErbB3-transfected wounds as compared to LacZ controls (data not
shown). A protein isolation was also conducted on this same wound
material from 48 hours after injury and the material was subjected to
Western blot analysis. The anti-human ErbB3 antisera (obtained from
Santa Cruz Biotechnologies, Santa Cruz, CA, no. SC-415) recognized
the full-length ErbB3 (B180 kDa in human) form as well as a soluble
B85 kDa (human) ErbB3 form in the positive control (normal non-
wounded pig skin) sample, but neither of the protein forms were
elevated in the non-treated wounds. In the experimental samples
48 hours after injury, the full-length protein form was not detected.
The smaller molecular weight form was detected in wounds
transfected with either Ad:ErbB3 or LacZ controls (Figure 8). To
control for effects of wound location on the rate of healing, the
various cytokine-treated wounds were spatially randomized on the
dorsum of the pig. Wound healing parameters selected for
evaluation in this study included re-epithelialization, neodermal
depth, thickness of the granulation tissue, macrophage infiltration,
numbers of proliferating cells, numbers of apoptotic cells, and the
density of the microvasculature. This report contains our report of
the assessments collected on the fifth post-injury day. Other time
periods were evaluated but were not performed in sufficient numbers
to provide statistical data.
Histological preparation and immunohistochemistry
After tissue slices were processed and embedded in paraffin, 5 mm
thick sections were cut using a microtome (Microm HM315).
For histological evaluation of dermal depth, granulation tissue,
and extent of re-epithelialization, tissue sections were stained
with Gomori’s Trichrome and subsequently examined and
measured.
Microvascular density. The extent of the capillary network within
the granulation tissue or the neodermis was illuminated by
immunostaining using antisera for Von Willebrand Factor (Dako,
Carpinteria, CA). Tissue sections were deparaffinized in xylene and
rehydrated in graded ethanols. Sections underwent antigen retrieval
using 5 minutes of digestion with Proteinase K (Dako). Following
rinses and endogenous blockade with hydrogen peroxide, sections
were incubated at 251C in rabbit polyclonal antisera for Factor VIII-
related antigen (Von Willebrand Factor) for 30 minutes with a
dilution of antibody at 1:900. Following this incubation in primary
antisera, the sections were processed through the reagents supplied
by rabbit Envisionþ System, HRP kit (Dako).
Cell proliferation. Actively replicating cells were selectively
highlighted within tissue samples by immunostaining with the Ki67
antigen. Endogenous peroxidase activity was neutralized followed
by a casein-based protein block (Dako) for nonspecific staining
blocking. The sections were incubated with rabbit anti-human Ki67
(NovaCastra Laboratories Ltd, Newcastle, UK) diluted at 1:1,400 for
60 minutes. The rabbit Envisionþ HRP/DAB System (Dako) was used
to produce localized, visible staining.
Macrophage detection. The extent of the inflammatory process
was gauged by the number of infiltrating macrophages at a
standardized time point (5 days after injury). Tissue sections
underwent heat-induced antigen retrieval at a high pH solution in
0.01 M Tris/HCL pH 10, rinsed, endogenous peroxidase activity
blocked during a 10 minutes treatment with hydrogen peroxide
followed by protein block for 20 minutes. Monoclonal mouse anti-
human antibody was used to detect macrophages (MAC387, Serotec
Ltd, Oxford, UK). The dilution of the primary antibody was 1:1,000
and sections were processed through the reagents using mouse
Envisionþ HRP kit (Dako).
Apoptosis detection. Fragmented DNA of apoptotic cells was
visualized with the DeadEnd Colorimetric TUNEL System (Promega
Corporation, Madison, WI). Tissue sections were subjected to a
second fixation in 4% paraformaldehyde, rinsed, and permeabilized
with proteinase K for 5 minutes. Sections then were treated with
equilibration buffer (Promega) followed by biotinylated nucleotide
incorporation into apoptotic cells using TdT. Endogenous peroxidase
was neutralized by applying 0.3% hydrogen peroxide to the



































































Figure 8. This Western Blot was performed on wound material derived at
48 hours after injury. The positive control lane shows successful detection of
both a full-length ErbB3 (B180 kDa) protein and a soluble ErbB3 receptor
(B85 kDa) protein form. The full-length ErbB3 protein was not detected
within any 48-hour samples. However, the solubleB85 kDa form showed an
increase in the wounds transfected with either Ad:ErbB3 or the Ad:LacZ. The
non-treated wound did not show an increase in soluble ErbB3 protein.
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diaminobenzidine produced apoptotic-specific visible nuclear stain-
ing. All slides were counterstained, dehydrated, and coverslipped.
Computerized morphometric wound analysis
For morphometric analysis, slides were placed under the light
microscope and were photographed using an Olympus model AHBT
camera. Quantitative measurements were performed using Image-
Pro Plus scientific image analysis software (Media Cybernetic Inc.,
Silver Spring, MD). To determine the average granulation tissue
thickness or neodermal depth in these partial-thickness wounds,
three to five random measurements were taken from the central area
within each wound bed (Nanney, 1990; Nanney et al., 2000).
Granulation tissue thickness was measured from the surface of the
granulating wound without epidermal resurfacing to its intersection
with the underlying non-wounded dermis. Neodermal depth was
measured from the dermo-epidermal junction to the intersection of
the overlying granulation tissue with the underlying non-wounded
dermis in these partial-thickness wound beds. All measurements in
this study were taken in microns using a defined magnification. The
epidermal resurfacing measurements were the sum of the new
epithelium at the wound edges combined with the epithelial islands
with the wound bed divided by the total wound length. These
resurfacing measurements were presented as percentage of the total
wound length in accordance with our previously reported assess-
ment technique (Nanney, 1990). For purposes of reporting of our
qualitative visual evaluations of epithelial maturity, a four-class
numerical system based on epithelial maturity was performed as
described herein: Class I: little or no epithelial layer; Class II: 1–3 cell
layer deep coverage with little or no stratification; Class III: normal
basal layerþ stratification of 3–7 cell layers; Class IV: basal layer
hyperproliferation, downward projections in neodermis.
The hallmarks of enhanced maturity within the wound bed were
evaluated by quantitative measurements that included neovascular-
ization, fibroblastic proliferation, numbers of infiltrating macro-
phages, and apoptosis. Factor VIII immunostaining selectively
highlights only the endothelial cells components, which facilitate
the identification of blood vessels (Roesel and Nanney, 1995;
Nanney et al., 2001). Five non-overlapping fields per section were
analyzed by the Image-Pro Plus software for the percentage of area
occupied by capillaries within a field area of 100,000 mm2. Vascular
densities included the sum of all the partial and complete
longitudinal and cross-sections of the capillary networks. Cell
proliferation, macrophage, and apoptotic cell densities were
expressed in numbers of cells in a field area of 20,000, 10,000,
and 10,000, respectively.
Statistical analysis
The results were expressed as means7SEM. The significance of the
differences between groups was determined by analysis of variance
and Bonferoni’s post hoc test.
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